Mogamulizumab-associated rashes may be related to improved therapeutic response in T-cell lymphomas. (September 2022) - Pileri, A; Clarizio, G; Zengarini, C; Casadei, B; Agostinelli, C; Sabattini, E; Zinzani, PL